Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Long-Term Foramen Ovale Closure after Cryptogenic Stroke

Patent foramen ovale closure is the standard treatment for cryptogenic stroke patients. However, there are is little information on its long-term evolution.

DEFENSE-PFO: el cierre FOP con ciertas características disminuye eventos combinados y strokeThe aim of this study was to determine clinical outcomes (death, ischemic or bleeding events) after foramen ovale closure over a 10-year evolution.

 

The study included 201 consecutive patients (mean age 47 ± 12, 51% women) receiving transcatheter patent foramen ovale closure in the context of cryptogenic stroke (stroke: 76%, transient ischemic attack: 32%, systemic embolism: 1%). Data on ischemic and bleeding events, and on antithrombotic drugs, was collected over mean 12 years (range 10 to 17) and follow-up was completed in 96% of the population.


Read also: New Device for More Protection in Carotid Artery Stenting.


The closure device was successfully implanted in all cases, with residual shunt in 3.3% of patients at echocardiographic follow-up.

 

At total 13 patients died at follow-up (all of non-cardiac cause); 2 patients presented non-disabling stroke and 6 presented transient ischemic attack (0.08 strokes/100 patients/year).

 

15% of the cohort presented a history of thrombophilia, which tended to be associated to more ischemic events at follow-up (p=0.067).


Read also: Is Tricuspid Regurgitation after TAVR Significant?


Bleeding events occurred in 13 patients; 4 were major bleeding events (intracranial). They were all under aspirin at the time.

 

A total 42 patients stopped the antithrombotic treatment at mean 6 months after foramen ovale closure and no patient presented events (ischemic or hemorrhagic) after 10 ± 4-year follow-up.

 

Conclusion

Foramen ovale closure was associated with a very low rate of ischemic events (<1% stroke) over 10 years after procedure. Major bleeding occurred in 2% of the population (all patients were under antiaggregants).

 

Patients that suspended all antithrombotic medication (mostly within a year after patent foramen ovale closure) presented no ischemic or bleeding events at long term follow-up.

 

Original title: Long-Term Follow-Up After Closure of Patent Foramen Ovale in Patients With Cryptogenic Embolism.

Reference: Jérôme Wintzer-Wehekind et al. J Am Coll Cardiol 2019;73:278–87.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...